TAMPA, Fla.--(BUSINESS WIRE)--Feb. 14, 2006--Accentia Biopharmaceuticals (Nasdaq:ABPI) was pleased to receive confirmation recently from the Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for the Company's proprietary drug SinuNase(TM) will remain under the direction of the Special Pathogens and Transplant Products (SPTP) section of the Centers for Drug Evaluation and Research (CEDR) of the Food and Drug Administration (FDA).
